Gastroenterology

Dietary amino acids are converted by the luminal microbiome in the gut to a bioactive compound, histamine, which binds to H2R and suppresses MAP kinase signaling and proinflammatory cytokines.

Natalizumab, a drug typically used to treat multiple sclerosis and Crohn's disease, has been shown to be effective in treating animal models of HIV.

The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.

The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.

In this video interview, Camille Barrault, MD, spoke about the implications her work with baclofen could have for the future of liver disease research at The International Liver Congress 2015, Vienna, Austria.

As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.

Video Interview: Vinood Patel, PhD, PGCHE, fHEA, FRSC, University of Westminster, London, UK, shared valuable insight regarding chronic alcoholic demographics and biomarkers on the horizon at The International Liver Congress 2015.

A new antiviral combination is showing promise in treating patients with both chronic kidney disease and chronic hepatitis C, Texas researchers reported at the International Liver Congress in Vienna, Austria.

Video Interview: Camille Barrault, MD discussed how her experiences with alcohol dependent patients correlated with her team's current research at The International Liver Congress 2015, Vienna, Austria.

When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.

For inflammatory abdominal aortic aneurysm, is open surgery or endovascular repair a better choice?

Researchers in India have found a reliable and sensitive marker to predict how close to organ failure seriously ill patients with liver disease may be.

Active immunization for hepatitis B can be a cheaper, safe way to prevent infections that occur when liver transplant recipients are infected by donors' organs.

After partial hepatectomy, the liver does not need an environment rich in microbes and microbial products to regenerate, a Swiss team reports. The finding contradicts earlier studies.

A new antiviral combination that shows dramatic results in getting a response from patients with both chronic kidney failure and hepatitis C is proving versatile.

Video Interview: Palak Trivedi, BSc, MBBS, MRCP, University in Birmingham, England, spoke about several drug candidates under review working to improve outcomes of liver blood tests at The International Liver Congress 2015, Vienna, Austria.

Translational medicine should work for many patients with liver cancer, a French research team reported this morning at the 2015 International Liver Congress.

In this video interview, Palak Trivedi, BSc, MBBS, MRCP, from the University of Birmingham Centre for Liver Research, United Kingdom, discussed the implications his research findings have for IBD patients at The International Liver Congress 2015 in Vienna, Austria.

So far there are no approved pharmaceuticals for treating a common liver disease, non-alcoholic steatohepatitis (NASH). But in a second encouraging drug development reported at the International Liver Congress in Vienna, Austria this morning, Austria, researchers said they like what they see in a trial of Liraglutide (Saxenda/ NovoNordisk).

An investigational diabetes drug called remogliflozin etabonate appears to also show promise for treating a common liver disease, non-alcoholic steatohepatitis (NASH) and its precursor non-alcoholic fatty liver disease (NAFLD).

High levels of vitamin D3 appear to induce weight gain in mice that were fed a high-fat diet, a research team found.

Many studies have looked at the link between vitamin D deficiency and liver disease. A Korean team recently examined whether vitamin D deficiency played a pivotal role in abnormal liver enzymes.

The intracellar lipid deposition, mitrochondrial dysfunction, and insulin resistance associated with non-alcoholic fatty liver disease is likely regulated by microRNAs, particularly in obese patients.

Patients with severe cirrhosis, those who are waiting for a liver transplant, or have recurrent hepatitis C infection following treatment are desperately ill. Researchers at the 2015 International Liver Congress reported that a fixed dose combination of ledipasvir/sofosbuvir given in combination with ribavirin helped many of these patients, according to the results from the SOLAR 2 trial.

An estimated 11,000 attendees from 105 countries are converging in Vienna, Austria for the 50th International Liver Congress, hosted by the European Association for the Study of the Liver (ILC/EASL). Some 200 journalists -- including a team from MD Magazine--are on hand to report the news. Eagerly awaited trials include those of two drugs that show promise for treating a common liver disease associated with obesity, known medically as non-alcoholic steatohepatitis (NASH) and its precursor non-alcoholic fatty liver disease (NAFLD).

Palak Trivedi, BSc, MBBS, MRCP, University in Birmingham, England, shared his fascination with the enigma that is primary sclerosing cholangitis.

Stepping out into the sun may be more important than ever, especially for patients with multiple sclerosis.

In a case reported in a poster session, a team describes a patient whose infection with E. cloacae caused a stroke.

While abnormal eating behaviors are recognized in behavioral frontotemportal dementia (bvFTD) patients, not much has been reported has been found on the effects on their metabolic health until recently, according to lead author Rebekah Ahmed, MD. The study is due to be presented in a poster session on Apr. 20 at the American Academy of Neurology meeting in Washington, DC.

Soligenix, Inc., a late-stage biopharmaceutical company, recently announced that the US Food and Drug Administration (FDA) authorized a pivotal Phase 3 clinical trial to assess the efficacy of novel drug SGX203, a pediatric Crohn's disease (CD) therapy.